Gilead Sciences is coming off of a milestone year that saw the start of the much-anticipated launch of the world’s first twice-yearly injectable HIV pre-exposure prophylaxis (PrEP) medicine Ye | ...

Clock’s ticking. After an expected FDA nod for Descovy as the second HIV PrEP drug, Gilead Sciences now has one year to convince its current Truvada takers to switch over before generics hit. The FDA ...

Today, the U.S. Food and Drug Administration approved Gilead’s drug Descovy to be used as PrEP, an HIV prevention strategy that when taken properly makes it virtually impossible to contract the virus ...

A major health insurer has notified policy holders that it will no longer cover Gilead Sciences’ drug Descovy for pre-exposure prophylaxis, or PrEP, and will instead require them to switch to Truvada, ...

Descovy demonstrated continued noninferiority to Truvada for HIV pre-exposure prophylaxis and statistically significant differences over Truvada for pre-specified secondary end points. In the phase 3, ...

George Froehle, PA, a primary care clinician at CentraCare in rural St. Cloud, Minnesota, has been prescribing the HIV prevention pill tenofovir disoproxil fumarate plus emtracitabine (TDF/FTC) since ...

The panel voted against recommending the prevention pill for use in cisgender women due to inadequate data on efficacy in this patient population. An FDA panel has backed Gilead’s HIV prevention drug ...

FOSTER CITY, Calif.--(BUSINESS WIRE)-- Gilead Sciences, Inc. (NASDAQ: GILD) today presented additional results from the DISCOVER trial evaluating an investigational use of Descovy (emtricitabine 200 ...

The U.S. Food and Drug Administration approved the second drug to help prevent HIV infections on Thursday. Descovy is a PrEP or pre-exposure prophylaxis drug, which means the drug is taken daily to ...

This post is part of Outward, Slate’s home for coverage of LGBTQ life, thought, and culture. Read more here. In October, the U.S. Food and Drug Administration approved the drug Descovy to be used as a ...